People · Operator
Named in public records as an officer, director or promoter · active 2012–2014 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gen9, Inc. | — | Biotechnology | Series B | $52.1M | $992.2M | 2012 |
| Vannevar Technology, Inc. | — | Other Technology | Series B | $46.7M | $883.2M | 2014 |
Stephen Jurvetson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Jurvetson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Stone | 1 | 12 |
| Steve Jurvetson | 1 | 10 |
| Paul Manning | 1 | 6 |
| Jeremy Wertheimer | 1 | 4 |
| Stanley Rose | 1 | 4 |
| Thomas Lamb | 1 | 3 |
| Weili Dai | 1 | 3 |
| Joseph Jacobson | 1 | 3 |
| Aaron Zucker | 1 | 2 |
| Eric Teller | 1 | 2 |
| Lawrence Silverstein | 1 | 2 |
| George Church | 1 | 2 |
| James Hollenhorst | 1 | 1 |
| Neil Cook | 1 | 1 |
| Jim Hollenhorst | 1 | 1 |
| Bill Scalzulli | 1 | 1 |
| Scott Schoen | 1 | 1 |
| Martin Goldberg | 1 | 1 |
| Wali Dai | 1 | 1 |
| Jamie Roche | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.